Department of Pharmaceutical and Administrative Sciences, College of Pharmacy, Western New England University, 1215 Wilbraham Road, Springfield, MA, 01119, USA.
Department of Physical Medicine and Rehabilitation, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
Ann Clin Microbiol Antimicrob. 2023 May 19;22(1):42. doi: 10.1186/s12941-023-00594-y.
This meta-analysis evaluated the Efficacy and Effectiveness of several COVID-19 vaccines, including AstraZeneca, Pfizer, Moderna, Bharat, and Johnson & Johnson, to better estimate their immunogenicity, benefits, or side effects.
Studies reporting the Efficacy and Effectiveness of COVID-19 vaccines from November 2020 to April 2022 were included. The pooled Effectiveness/Efficacy with a 95% confidence interval (95% CI) with Metaprop order was calculated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.
A total of twenty articles were included in this meta-analysis. After the first dose of the vaccine, the total effectiveness of all COVID-19 vaccines in our study was 71% (95% CI 0.65, 0.78). The total effectiveness of vaccines after the second dose was 91% (95% CI 0.88, 0.94)). The total efficacy of vaccines after the first and second doses was 81% (95% CI 0.70, 0.91) and 71% (95% CI 0.62, 0.79), respectively. The effectiveness of the Moderna vaccine after the first and second dose was the highest among other studied vaccines ((74% (95% CI, 0.65, 0.83) and 93% (95% CI, 0.89, 0.97), respectively). The highest first dose overall effectiveness of the studied vaccines was against the Gamma variant (74% (95% CI, 0.73, 0.75)), and the highest effectiveness after the second dose was observed against the Beta variant (96% (95% CI, 0.96, 0.96)). The Efficacy for AstraZeneca and Pfizer vaccines after the first dose was 78% (95% CI, 0.62, 0.95) and 84% (95% CI, 0.77, 0.92), respectively. The second dose Efficacy for AstraZeneca, Pfizer, and Bharat was 67% (95% CI, 0.54, 0.80), 93% (95% CI, 0.85, 1.00), and 71% (95% CI, 0.61, 0.82), respectively. The overall efficacy of first and second dose vaccination against the Alfa variant was 84% (95% CI, 0.84, 0.84) and 77% (95% CI, 0.57, 0.97), respectively, the highest among other variants.
mRNA-based vaccines against COVID-19 showed the highest total efficacy and effectiveness than other vaccines. In general, administering the second dose produced a more reliable response and higher effectiveness than a single dose.
本荟萃分析评估了几种 COVID-19 疫苗的疗效和有效性，包括阿斯利康、辉瑞、莫德纳、 Bharat 和强生，以更好地估计它们的免疫原性、益处或副作用。
纳入了 2020 年 11 月至 2022 年 4 月报告 COVID-19 疫苗疗效和有效性的研究。使用 Metaprop 顺序计算了合并的疗效/有效性及其 95%置信区间（95%CI）。结果以森林图呈现。还进行了预设的亚组分析和敏感性分析。
本荟萃分析共纳入 20 篇文章。在接种疫苗第一剂后，我们研究中所有 COVID-19 疫苗的总有效性为 71%（95%CI 0.65，0.78）。接种第二剂后的总有效率为 91%（95%CI 0.88，0.94）。接种第一剂和第二剂后疫苗的总疗效分别为 81%（95%CI 0.70，0.91）和 71%（95%CI 0.62，0.79）。莫德纳疫苗在第一剂和第二剂后的有效性在研究的疫苗中最高（分别为 74%（95%CI，0.65，0.83）和 93%（95%CI，0.89，0.97））。研究疫苗中第一剂的总体有效性最高的是针对伽马变异株（74%（95%CI，0.73，0.75）），第二剂后的最高有效性是针对贝塔变异株（96%（95%CI，0.96，0.96））。接种第一剂后阿斯利康和辉瑞疫苗的疗效分别为 78%（95%CI，0.62，0.95）和 84%（95%CI，0.77，0.92）。接种第二剂后阿斯利康、辉瑞和 Bharat 的疫苗疗效分别为 67%（95%CI，0.54，0.80）、93%（95%CI，0.85，1.00）和 71%（95%CI，0.61，0.82）。接种第一剂和第二剂疫苗对阿尔法变异株的总体疗效分别为 84%（95%CI，0.84，0.84）和 77%（95%CI，0.57，0.97），在其他变异株中最高。
针对 COVID-19 的基于 mRNA 的疫苗显示出比其他疫苗更高的总疗效和有效性。一般来说，与单剂接种相比，第二剂接种产生的反应更可靠，效果更高。
